US President Donald Trump says he’ll quickly announce “main” tariffs on imported prescribed drugs, a transfer that would finish a long time of low-cost international commerce in medicines.
For years, most nations, together with the US, have imposed few or no tariffs on completed medicine, thanks partially to a 1995 World Commerce Organisation (WTO) settlement aimed toward protecting medicines reasonably priced.
This shift comes after Trump launched a blanket 10% tariff on different imports final week, as a part of a broader effort to deliver manufacturing again to the US.
His new “reciprocal” tariffs – together with an obligation of 104% on items arriving from China – got here into pressure on Wednesday, intensifying a worldwide commerce battle and additional shaking markets.
Pharmaceutical patrons, up to now spared from such measures, are actually getting ready for what could come subsequent.
The US has sometimes imported huge portions of completed medicines from India, Europe and China with out patrons paying tariffs – though energetic pharmaceutical components (APIs), used to make medicine, do face some duties.
Talking at a fundraiser dinner for his Republican Get together on Tuesday, Trump mentioned: “We will be asserting very shortly a significant tariff on prescribed drugs. And once they hear that, they may depart China.”
He additionally advised reporters on board his Air Power One airplane final week that “pharma” tariffs would arrive “at a stage that you have not actually seen earlier than”, saying these can be introduced “within the close to future”.
In 2024, the US imported $213bn (£168bn) value of medicines – greater than two and a half instances the full a decade earlier.
Whereas brief on element, his feedback have rattled patrons, particularly these counting on Indian imports. India provides practically half of all US generics, or cheaper variations of well-liked medicine, saving the nation billions in healthcare prices.
Indian pharma shares fell sharply on the information. India sends a few third of its $13bn annual pharma exports to the US, which is a key market.
In the mean time, Individuals pay little or no tax on imports of Indian medicines – in contrast with the responsibility of practically 11% paid by Indians importing American medicines.
Indian drugmakers warn that tariffs would pressure them to lift costs, which may finally drive up US medical payments. Whereas companies like Cipla and Dr Reddy’s have US crops, most say transferring manufacturing will not be viable for low-margin generic medicine.
European drugmakers are additionally on alert. After a high-level assembly between European Fee President Ursula von der Leyen and prime pharma companies on Tuesday, the European Federation of Pharmaceutical Industries and Associations (EFPIA) warned that tariffs may shift manufacturing away from Europe, and to the US.
The EFPIA, whose members embrace main pharmaceutical corporations corresponding to Bayer, Novartis, and Novo Nordisk – the maker of the star diabetes kind 2 drug Ozempic – expressed considerations that rising tariffs may disrupt Europe’s position as a key participant in international pharmaceutical manufacturing.
In 2024, prescribed drugs had been the EU’s largest export to the US, value a reported $127bn (£100bn).
Main corporations have urged the EU to behave swiftly, in search of coverage adjustments to reinforce Europe’s competitiveness and stop a “mass exodus” to the US. They’ve additionally expressed considerations about potential EU retaliatory tariffs, which may disrupt provide chains and have an effect on sufferers on each side of the Atlantic.
World pharma giants like GSK and Pfizer function throughout a number of nations, together with Eire and Germany, that means new tariffs may disrupt a number of components of the provision chain.